Skip to main content

Advertisement

Table 4 Multivariate cox regression models for progression-free survival (PFS) and overall survival (OS) in the 33 cetuximab-treated patients

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

  PFS OS
HR 95 % CI P value HR 95 % CI P value
Smoking history    0.268    0.786
 Ex-smoker 1.0    ND   
 Smoker 2.2 0.2–20.9   ND   
 Non-smoker 0.4 0.2–1.9   ND   
Primary site    0.184    0.389
 Larynx 1.0    1.0   
 Oropharynx 0.3 0.5–2.2   0.3 0.1–4.6  
 Oral cavity 2.8 0.4–10.2   2.1 0.4–6.3  
 Hypopharynx 2.1 0.3–8.3   2.6 0.1–10.2  
Histological grade    0.090    0.719
 Well-differentiated 1.0    1.0   
 Moderately differentiated 4.6 2.5–7.6   0.9 0.1–3.2  
 Poorly differentiated 3.2 2.3–8.5   1.9 0.1–4.1  
Alcohol 2.1 0.7–10.3 0.381 6.2 0.1–34.2 0.413
MET overexpression 7.6 4.6–10.4 0.060 4.9 0.1–8.5 0.070
p-MET overexpression 6.5 1.5–8.9 0.002 8.2 0.2–14.6 0.022
HGF overexpression 6.6 1.2–8.4 0.059 2.2 0.2–2.1 0.110
  1. Firstly, univariate analysis was performed for the descriptive variables, and then we executed a multivariate analysis on those significant variables. Since MET, p-MET and HGF expression are associated with each other, we performed separate analysis for each marker
  2. HR hazard ratio, CI confidence interval, ND not enough data available